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Lyprinol—is it a Useful Anti-inflammatory Agent?
Sheila A. Doggrell
School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, QLD4001, Australia
The New Zealand green lipped mussel preparation Lyprinol is available without a prescription
from a supermarket, pharmacy or Web. The Food and Drug Administration have recently
warned Lyprinol USA about their extravagant anti-inflammatory claims for Lyprinol appearing
on the web. These claims are put to thorough review. Lyprinol does have anti-inflammatory
mechanisms, and has anti-inflammatory effects in some animal models of inflammation.
Lyprinol may have benefits in dogs with arthritis. There are design problems with the clinical
trials of Lyprinol in humans as an anti-inflammatory agent in osteoarthritis and rheumatoid
arthritis, making it difficult to give a definite answer to how effective Lyprinol is in these
conditions, but any benefit is small. Lyprinol also has a small benefit in atopic allergy. As
anti-inflammatory agents, there is little to choose between Lyprinol and fish oil. No adverse
effects have been reported with Lyprinol. Thus, although it is difficult to conclude whether
Lyprinol does much good, it can be concluded that Lyprinol probably does no major harm.
Keywords: Lyprinol – anti-inflammatory – animal models of inflammation – clinical trials –
arthritis in dogs
Introduction
The New Zealand green lipped mussel preparation
Lyprinol is readily available without a prescription from
a supermarket, pharmacy or web. Over the years,
‘Miracle from the sea’, and many other claims have
been made about the therapeutic benefits of Lyprinol
(1). In 1999, there was the extraordinary situation of
Lyprinol being promoted and marketed as an anti-
cancer agent (2). As a consequence, patients bought
large quantities of this product at significant expense
(NZ$2 million), despite there being no evidence of effi-
cacy (3). The Therapeutics Goods Administration in
Australia advised cancer patients not to rely on this sub-
stance for the treatment of their cancer, and to seek
medical advice.
More recently, Lyprinol has been promoted for its anti-
inflammatory effects. The starting point for the interest in
the green lipped mussel as therapy for inflammation was
folklore. This folklore was that coastal dwelling Maori in
New Zealand, who regularly consumed mussels as part of
their diet, suffered far less from the ravages of arthritis
than their inland dwelling relatives (1).
The trade mark for Lyprinol is held by Pharmalink,
who state that ‘Lyprinol has been usefully for the treat-
ment of osteoarthritis, rheumatoid arthritis, asthma and
gout and is being studied for its effectiveness against
the other inflammatory diseases such as Crohn’s disease,
ulcerative colitis, lupus, psoriasis and others’ (4).
Lyprinol is marketed on the net by NZ Nutraceuticals,
which states it has ‘clinically proven anti-inflammatory
properties’, and that ‘as an effective anti-inflammatory
agent, Lyprinol is used to treat arthritis, osteoarthritis,
rheumatoid arthritis, asthma, muscle pain (particularly for
sports people)’ (5). Lyprinol is marketed in Australia
by Blackmores, and the packet states ‘Its potent anti-
inflammatory actions assist in the maintenance of healthy
airways and breathing passages, as well as providing
relief from joint swelling and arthritis.’
As recently as 2007, The Food and Drug Administra-
tion warned LyprinolUSA about their extravagant
anti-inflammatory claims for Lyprinol appearing on
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the web (6). LyprinexTM also contains Lyprinol and is
marketed internationally, including on the web by Life
Plus International (7). LyprinexTM claimed ‘Lyprinol
has been shown to improve the following conditions:
Inflammation; Pain due to inflammation; Bronchial tight-
ness; Allergy symptoms. Additional benefits: (Lyprinol)
May lower depression: May reduce the risk of coronary
heart disease. It (Lyprinol) improves the condition of
patients with rheumatoid arthritis: it improves the condi-
tion of patients with asthma (7).’
There were some initial problems with extracting the
ingredients from Perna canaliculus, the NZ green lipped
mussel, as most of the activity was lost with heat treat-
ments or freeze drying (1). Thus, some of the early
studies may have been carried out with preparations
with no active ingredients, and (not surprisingly), an
anti-inflammatory action was not consistently reported
(1). The process now being used to extract the ingredients
from the mussels does result in Lyprinol having active
ingredients (8). As these extraction problems were
sorted out by 1990, only publications from 1990 onwards
are considered in this review. In addition to Lyprinol
(also known as Seatone) and products derived from
Lyprinol, Perna (the lyophilized P. canaliculus powder)
is active, and is discussed in this review.
MobicosaTM is a new freeze-dried preparation of the
green lipped mussel which in addition to the fatty acids
reported in Lyprinol (see next section) contains other nat-
ural agents (glucosamines and chrondroitin sulphates)
(9). These compounds have been claimed to have benefits
in arthritis in their own right. Consequently, it is difficult
to determine whether any benefits of MobicosaTM are
due to the fatty acids in the P. canaliculus, or the gluco-
samines and chrondroitin. For this reason, and also
because, to my knowledge, there are no published studies
of the effects of MobicosaTM in clinical trials in animals
or humans, MobicosaTM is not included in this review.
This review is a thorough review of Lyprinol as an anti-
inflammatory agent. Pubmed and the Internet were
searched for references to Lyprinol, Seatone and Perna
alone, available from 1990 onwards. In the first part of
the review, the anti-inflammatory mechanisms of actions
of Lyprinol/Seatone/Perna are discussed. This is followed
by a review of the evidence for anti-inflammatory
effects with Lyprinol/Seatone/Perna in animal models.
The major emphasis of this review is the clinical trials
with Lyprinol, which are critically discussed. Fish oil is
another complementary medicine that is used as an
anti-inflammatory agent. Fish oil has some of the same
ingredients as Lyprinol, and the final part of the review
considers studies that have compared fish oil and
Lyprinol as anti-inflammatory agents. The search
words for this final part of the review are fish oil and
Lyprinol/Seatone/Perna and inflammation or anti-
inflammatory.
Contents of Lyprinol
Lyprinol is a mixture of the five main lipid classes includ-
ing sterol esters, triglycerides, free fatty acids, sterols
and polar lipids (1). Lyprinol contains two of the long
chain omega-3 polyunsaturated fatty acids (PUFAs);
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) (1). In amounts, Lyprinol is 13% EPA, 21%
DHA and about 30% cholesterol (10). Additionally,
Lyprinol contains some novel o-3 PUFAs; 5,9,12,
15-octodecatretraenoic acid, 5,9,12,16-nondecatertraenoic
acid, 7,11,14,17-eicosatetraenoic acid, and 5,9,12,15,
18-heneicsapententaenoic acid (11). EPA and DHA are
the main ingredients of fish oil supplements. Thus,
there will be similarities between Lyprinol and fish oil,
which are discussed later in this review.
EPA, DHA and the o-3 PUFA 7,11,14,17-eicosatetrae-
noic acid are similar in structure to arachidonic acid
(5,8,11,14-eicosatraenoic acid), the precursor to the
inflammatory agents, prostaglandins and leukotrienes.
Thus, it is probably not surprising that Lyprinol can
modulate the effects of these inflammatory agents to
exert an anti-inflammatory effect.
Anti-inflammatory Mechanisms of Action
of Lyprinol
As competitive substrates for the cyclooxygenase enzyme
(COX; synthesis of prostaglandins) and the lipoxygenase
enzyme (synthesis of leukotrienes), EPA and DHA reduce
the levels of the inflammatory prostaglandins and leuko-
trienes. Lyprinol also does this, presumably (at least
partly) due to the EPA and DHA content. In human
monocytes, PGE2 production from arachidonic acid was
inhibited by Lyprinol with an IC50 of 1.2mgml
–1 (12).
With human polymorphonuclear leukocytes in the pres-
ence of arachidonic acid, Lyprinol (100mgml–1) abolished
the formation of leukotrienes (LT) B4 and reduced the
formation of 5-HETE (products from the lipooxygenase
pathways) (12). The free fatty acids from Lyprinol have
also been shown to inhibit the formation of LTB4 and
5-HETE from human neutrophils stimulated with arachi-
donic acid and a calcium ionophore (11).
Lyprinol also has a direct ability to inhibit the COX
enzymes (COX-1 and COX-2) (13). COX-2 is the induci-
ble enzyme commonly associated with excessive inflam-
mation. Thus, P. canaliculus at 1 mgml–1 inhibited COX-1
and COX-2 by 12% and 25%, respectively (13). After
hydrolysis to the free fatty acid fraction, inhibition was
increased to 49% for COX-1 and 60% for COX-2, and
when the free fatty acids were separated, inhibition was
increased further to 78% for COX-1 and 70% for COX-2
(13). Both the Tween-20 extract and the glycogen extract
of Perna (Aroma NZ Ltd), which is lyophilized P. cana-
liculus powder, have been shown to inhibit COX-1 and
COX-2 (14).
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In addition to prostaglandins and leukotrienes, hista-
mine and cytokines are mediators of inflammation.
In 1986, there was a brief report of anti-histaminic activ-
ity with P. canaliculus (15). Recently, Lyprinol has been
shown to decrease the ability of lipopolysaccharide (LPS)
to stimulate tumour necrosis factor-alpha (TNF-a) and
interferon-gamma (IFN-g) in splenocytes from a rat
model of arthritis, where Freund’s complete adjuvant
containing Mycobactrium butyricum was injected into
the paw (16). The levels of TNF-a and IFN-g were
raised in untreated arthritis to 3.1 and 10.7 ngml–1, and
after Lyprinol treatment were decreased to 1.71 and
3.0mgml–1, respectively (16).
Perna has also been shown to reduce the concentrations
of TNF-a and interleukin (IL)-12p40 production from
LPS stimulated human THP-1 monocytes (17). In addi-
tion to inhibiting TNF-a, Tween-20 extracts of Perna
have been shown to inhibit the production of IL-1,
IL-2 and IL-6 in isolated cell preparations, and also to
inhibit IgG production (14).
Recently, proteomics in the splenocytes from the
rat model of arthritis induced by M. butyricum has
shown changes in protein expression with Lyprinol, but
it is not clear whether these changes relate to the anti-
inflammatory effect of Lyprinol. Thus, Lyprinol changed
the expression of several proteins related to metabolism
(increased expression of malate dehydrogenase, and
decreased expression of protein-o-mannosyl-transferase
2,titin-cap protein, and protein disulfide isomerase) and
decreased expression of Tdrd7, telethonin and dynactin
(18). The authors hypothesize that these changes in pro-
teins related to metabolism may be responsible for the
anti-inflammatory effects of Lyprinol. Many further
experiments are required to test this hypothesis including
testing whether Lyprinol alters the expression of these
proteins in other models of inflammation, and what, if
any, is the relationship between these proteins and the
anti-inflammatory effects of Lyprinol.
Lyprinol in Animal Models of Arthritis
Carrageenan Model
In one of the standard models of arthritis used in exper-
imental studies of arthritis, the injection of carrageenan
into rear paws of rats to induce swelling, Lyprinol
showed little activity (12). However, Lyprinol has been
shown to reduce swelling in other animal models of
arthritis.
Collagen Type-II-Induced Arthritis
Collagen type-II-induced arthritis is another established
animal model of human arthritis, and in this model,
Lyprinol does suppress inflammation (12). In this
model, the collagen is emulsified with complete
Freund’s adjuvant and injected into the rear right paw
of the rat (12). The amounts of paw swelling were 1.77
and 1.62mm in the rear left and right rear paws, respec-
tively, and this was reduced to 0.32 and 1.04mm with
Lyprinol (20mgkg–1) and to 0.82 and 1.48mm with ibu-
profen (50mgkg–1) (12).
Glucocorticoids are the standard treatment of severe
arthritis, and when new drugs are developed for arthritis,
they are compared to the glucocorticoids, as only if
agents can be shown to be better or additive with gluco-
corticoids are they likely to have a role in clinical prac-
tice. When collagen type-II in Freund’s incomplete
adjuvant was used to induce arthritis in rats, Lyprinol
at 20mg kg–1 had no effect alone on paw swelling, nor
did the glucocorticoid prednisone at 2.5mg kg–1 alone
(19). However, when these agents were combined, at
the same doses, the paw swelling was reduced (19). Key
studies comparing Lyprinol to an effective dose of gluco-
corticoid, or with an effective dose of glucocorticoid,
have not been reported in this standard model or
arthritis.
Perna has also been tested in the collagen type-II-
induced severe polyarticular arthritis model in the rat
and mouse (17). In the rat, when Perna 100mgkg–1 day–1
treatment was started at the same time as the collagen
type II, there was a reduction in the incidence of develop-
ing arthritis from 58% in the control group to 17% in the
Perna group (17). In the mouse with established arthritis,
Perna had no effect on the arthritis scores after 10 days,
but reduced the score by day 81 (17).
Zymosan-Induced Inflammation
Zymosan is commonly used as a local irritant to cause
acute inflammation. Pentoxifylline acts to reduce the
levels of the inflammatory interleukins and TNF-a.
Lyprinol had an additive effect with pentoxifylline in
rat zymosan models of arthritis. Thus, in zymosan-
induced paw swelling, pentoxifylline (125mgkg–1) and
Lyprinol (20mg kg–1) alone reduced paw swelling by
15–20%, and in combination by about 50% (20).
Mycobacterium tuberculosis
When chronic polyarthritis was induced in rats using
adjuvant, prepared from dried M. tuberculosis, inoculated
into the tailbase, Lyprinol pre-treatment (20mg kg–1 with
continued treatment) reduced paw swelling (12). The level
of swelling in the front and rear paw group after adju-
vant treatment was 2.8mm and 1.2mm, and this was
reduced to 1.4mm and 0.23mm, respectively, by
Lyprinol (12). Lyprinol 20mg kg–1 had a greater effect
in reducing paw swelling in this model of arthritis than
the standard non-steroidal anti-inflammatory agents:
eCAM 2009 3 of 8
aspirin (300mgkg–1), ibuprofen (40mgkg–1) or naproxen
(25mgkg–1) (12).
When arthritis was induced in rats using adjuvants
prepared from dried M. tuberculosis, Lyprinol alone at
20mgkg–1 had little effect, and the glucocorticoid predni-
sone at 2.5 or 10mgkg–1 had no effect alone (19).
This suggests that this is a relatively glucocorticoid-insen-
sitive model of arthritis. However, when the lower dose
of prednisone was combined with Lyprinol there was a
reduction in paw swelling, and this reduction was greater
than with Lyprinol alone (19). The COX inhibitors, aspi-
rin (200mgkg–1), diflunisal (80mg kg–1) and mefenamic
acid (150mgkg–1) were also ineffective alone in this
model, but were effective when combined with Lyprinol
20mg kg–1 (19). The free fatty acids of P. canaliculus
mussel powder at 30mgkg–1 have recently been to have
a similar ability to piroxicam (2mgkg–1) to reduce the
swelling induced by adjuvants prepared from dried
M. tuberculosis (21).
Pain was the main focus of a study where arthritis was
induced in rats by injecting Freund’s complete adjuvant
containing M. butyicum into the hind paw, Lyprinol
25mg kg–1 reduced the swelling (16). Associated with
this reduction in swelling, there was initially a similar
reduction in pain score (vocalizations during flexions of
the paw) with Lyprinol and naproxen (20mgkg–1) (16).
The pain reduction was maintained in the presence of
naproxen but not Lyprinol (16). In splenocytes from
this model at 14 days, Lyprinol and naproxen treatment
were associated with a similar reduced ability of LPS to
stimulate TNF-a and IFN-g (16).
Pentoxifylline (125mgkg–1) and Lyprinol (20mg kg–1)
alone had no significant effect on the swelling in
pre-established M. tuberculosis induced arthritis to a
small extent, induced arthritis, whereas in combination
the swelling was reduced to a small extent (20).
Lyprinol in Other Animal Models of Disease
There is some preliminary evidence that Lyprinol may be
potentially useful in ameliorating the symptoms of inflam-
matory bowel disease. Thus, in a mouse model of inflam-
matory bowel disease induced by dextran sulphate sodium,
Lyprinol (Pharmalink International) 5mg per day reduced
body weight loss, decreased disease activity in the colon,
and reduced the distal colon crypt area losses (22).
Intestinal mucositis is a common and debilitating side
effect of some kinds of chemotherapy including that with
5-fluorouracil. In a rat model where 5-fluorouracil was
used to cause intestinal mucositis, Lyprinol prevented
weight loss and histological damage severity (23).
Lyprinol has also been shown to reduce the contrac-
tions of the isolated rat uterus, and it has been suggested
that it may be useful for the treatment of dysmenorrhoea
(24). An advantage Lyprinol had over the NSAIDs
(aspirin, ibuprofen and naproxen), was that it did not
induce gastric lesions in rats (24).
Studies of Lyprinol in Dogs with Arthritis
Studies have shown that Lyprinol is effective in treating
dogs with arthritis. In 2001, it was shown that when dogs
with osteoarthritis were fed with P. canaliculus, there
was an improvement compared to untreated dogs (25).
Three placebo-controlled studies involving 96 arthritic
dogs were undertaken where the Perna (450, 750 and
1000mg for dogs 525, 25–34 and 434 kg, respectively)
was added to the top of standard food, incorporated
into a treat or incorporated into the food (25). All the
studies had similar findings; showing that after 6 weeks,
compared to placebo, Lyprinol was beneficial. Arthritis
scores were of mobility, and the pain, swelling and
crepitus of individual joints and of each limb. When
P. canaliculus was added to the standard food, it reduced
the scores compared to the untreated dogs (25). When the
individual items of the arthritis scores were separated,
it was shown that there was a major decrease in the
pain score and a modest reduction in joint swelling and
crepitus (25).
However, these results were not substantiated in a
12-week trial comparing Green shell mussel powder
(11mg) to chondroitin sulphate and placebo in 58 dogs
with degenerative joint disease of the shoulder, elbow, hip
joints, and/or stifle (26). Both owners and veterinarians
reported a slight improvement of the symptoms in all
three groups (i.e. including the placebo group) (26). It
has been suggested that the mussel extract was ineffective
in this study due to the low dose (27).
A further study showed that at 125mg, Green lipped
muscle extract was effective in dogs with degenerative
joint disease (27). This trial used 81 lame dogs, compared
the mussel extract to placebo, and assessed the severity of
musculoskeletal dysfunction (27). Although there was no
improvement after 28 days, by 56 days, 67% of the lame
dogs were showing improvement in the mussel group,
compared to 41% in the placebo group (27). However,
by day 112, there was no significant difference between
the groups (27). No adverse effects or toxicity was noted
with the mussel extract in dogs (27).
In 2007, Perna was compared to placebo and the non-
steroidal anti-inflammatory drug carprofen in 45 dogs with
chronic pain due to osteoarthritis (28). In this study, the
placebo group showed a 20–40% improvement in pain/
chronic pain, the veterinary mobility index, locomotion,
and force exerted by the most effected leg, after 8 weeks
(28). The pain VAS improved by 67% with Perna and 86%
with the non-steroidal anti-inflammatory drug carprofen
(28). Carprofen was also more effective than Perna in
improving the force exerted by the leg (67% vs 47%; pla-
cebo 27%) (28). Perna and carprofen caused similar
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improvements in chronic pain (80%; placebo, 20%) and
the veterinary mobility index (67%; placebo, 27%) (28).
Clinical Trials with Lyprinol in Humans
Clinical trials of the effects of Lyprinol in subjects with
arthritis and asthma have been reported, and are
described in this section. The question, this part of the
review asks, is whether Lyprinol has been shown to be
anti-inflammatory in humans? After searching and col-
lecting all the information found on Pubmed and the
Internet for Lyprinol/Seatone/Perna from 1990 onwards,
the clinical trials in inflammation were selected, and all of
these are reviewed. Most of the clinical trials with
Lyprinol have flaws. It was decided not to exclude any
of these, but to present the results of each clinical trial in
sequence, with a discussion of any problems with the
methodology and interpretation of results in the trial.
To my knowledge, there are no ongoing clinical trials
with Lyprinol. Some clinical trials that have previously
been reported to be in progress (Crohn’s disease, ulcera-
tive colitis, lupus, psoriasis), but have not been reported.
The clinical trials presented show that there is some evi-
dence that Lyprinol may have a small efficacious effect in
osteoarthritis and rheumatoid arthritis.
Osteoarthritis and Rheumatoid Arthritis
In 1998, the effects of the stabilized green-lipped mussel
powder 1150mg per day (five capsules, Group A) was
compared to that of the lipid extract 210mg per day
(three capsules, Group B) in subjects with osteoarthritis
and rheumatoid arthritis at the outpatients’ clinic of the
Glasgow Homoeopathic Hospital (29). Both groups
(A and B) had 15 subjects with osteoarthritis and 15
subjects with rheumatoid arthritis (29). Most of the sub-
jects with osteoarthritis were taking non-steroidal anti-
inflammatory drugs, while half of the subjects with
rheumatoid arthritis were taking second line drugs (29),
which were not specified. In osteoarthritis, there were
improvements after 3 months of articular index, morning
stiffness and functional index with both preparations.
Thus, in subjects with osteoarthritis in Group A, the
articular index decreased from a baseline of 9.5 to 4.3,
morning stiffness from 52.5 to 24.3, and the functional
index from 10.4 to 4.8 (29). In subjects with rheumatoid
arthritis in Group A, articular index decreased from a
baseline of 14.8 to 5.9, morning stiffness from 98.4 to
27.1, and the functional index from 12.9 to 6.9 (29).
Similar results for these parameters were obtained in
Group B. Similar reductions in pain scores were obtained
in the subjects with osteoarthritis in Group A (6.1 to 4.8)
and Group B (6.1 to 5.0), but this was only significant in
Group B (29). In rheumatoid arthritis, both preparations
of Lyprinol improved articular index, morning stiffness
and functional index to a similar extent as in osteoarthri-
tis, and there was no significant improvement in pain
scores (29). Neither preparation improved grip strength
in the right or left hands of subjects with either osteoar-
thritis or rheumatoid arthritis (29).
A major flaw in this trial was that there was not a
placebo group, and we will never know for certain
whether these effects of the Lyprinol were greater than
the placebo effect. The authors argue that the placebo
effect is small in arthritis (29), but without a placebo
group we cannot tell whether this would have been so
in this protocol. Recent placebo-controlled trials suggest
that there is about a 20% reduction in osteoarthritis
symptoms with placebo. Thus, in a 12-week placebo-
controlled trial of tramadol in osteoarthritis of the
knee, there was about a 20% reduction in pain, stiffness
and physical function with placebo (30). In trials of dia-
cerein and othokin in osteoarthritis, the placebo also
reduced pain by about 20% at 3 months (31,32). The
reductions in articular index, morning stiffness and func-
tional index with the mussel powder or lipid extract were
about 55%, which (if we accept 20% as the placebo level)
suggests that Lyprinol does have benefits on these symp-
toms. Lyprinol reduced pain by 20% in the clinical trial
with the mussel powder or lipid extract (29), which is
comparable to the placebo effect in placebo-controlled
trials in osteoarthritis. This suggests that Lyprinol is
having little or no effect on the pain associated with
osteoarthritis.
Osteoarthritis
There was another study suggesting that Lyprinol was
effective in relieving the pain osteoarthritis, published in
2003. All 54 patients heard detailed information about
Lyprinol, and were treated with Lyprinol (two capsules
bid) (33). After 8 weeks, of 56 subjects with hip and knee
osteoporosis, there was a reduction in pain from 6.4 cm
on the Visual Analogue Scale to 3.9 (33), a 39% reduc-
tion. A similar percentage benefit was observed with
Lyprinol in joint function (33). At 8 weeks, 87% of
patients and 90% of doctors reported improved in
global assessment (33).
To be properly controlled, this clinical trial should have
provided information to all participants about placebo,
and compared Lyprinol with a control group receiving a
placebo. Without this control group it is difficult to
determine whether Lyprinol was effective, or it was a
combination of the information and placebo effect that
was effective in the group treated with Lyprinol. There is
also a discrepancy between this study showing a reduc-
tion in pain of 39% with Lyprinol in osteoarthritis (33)
to the previous study showing a reduction in pain of 20%
[discussed in previous section (29)], which is equivalent to
the placebo response. There are several possible reasons
for this discrepancy. For instance, the doses of Lyprinol
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are not in the same range but not identical in the two
studies, and the length of the studies are different
(3 months versus 8 weeks). Another reason for the dis-
crepancy could be that there was a positive response to
the information in the Lyprinol group.
The final trial of Lyprinol in osteoarthritis was placebo-
controlled and reported in 2004 (33). In this trial,
80 subjects with knee osteoarthritis were randomized on
a double-blind manner to Lyprinol or placebo (34). Pain
scores decreased in both groups, and were lower for
Lyprinol than placebo after 8 and 12 weeks (VAS of
51mm versus 57mm at both time points), but not
18 weeks (VAS of 53 versus 56) (34). The patients’
global assessment of their arthritis showed improvement
in both groups, and was only significant greater for
Lyprinol after 12 (2.8 vs 3.2 in the placebo group) and
18 weeks (3.0 vs 3.1) (34). However, there was no differ-
ence in the physicians’ global assessment of arthritis
between groups (34). In this study, the reductions in
pain scores and the patients’ assessment of improvement
with Lyprinol were quite small. Also, as both groups
were allowed to take unlimited paracetamol, there was
great variability in the intake of paracetamol in both
groups calculated as a percentage of baseline intake
(34). Without the absolute amounts of paracetamol
taken by the subjects, it difficult to assess whether para-
cetamol contributed to the small reduction in pain
observed with Lyprinol.
Rheumatoid Arthritis
Lyprinol in combination with fish oil has been tested in
50 adults with rheumatoid joint disorder, moderate pain
and morning stiffness (35). After 12 weeks of treatment,
the mean duration of morning stiffness was reduced from
13.7 to 12.4min, the number of painful joints from 4.18
to 3.58, and the number of swollen joints from 2.62 to
1.94 by the combination of Lyprinol and fish oil (35).
Pain was evaluated separately by the patients and physi-
cians, and was also reduced with the combination treat-
ment (35).
The two most obvious criticisms of this study, is that
there was no placebo group, and thus we do not know
whether the small benefits observed were a placebo
response or due to the combination of Lyprinol and
fish oil. Secondly, if we concede that there may be a
small beneficial response, we cannot determine whether
it is due to Lyprinol, fish oil or the combination? For
instance, if fish oil was effective, and Lyprinol was not,
the combination could still show benefit.
Asthma
A small clinical trial suggests that Lyprinol may be useful
against some of the symptoms of atopic (allergic) asthma.
The 46 subjects in this trial has mild asthma with
symptoms twice a week or less with a FEV1 (the forced
expiratory volume in one second) of 80% of predicted,
and were using short-acting b-adrenoceptor agonists for
symptom relief (36). Subjects receive either two tablets
bid of either Lyprinol or placebo for 8 weeks. Lyprinol
reduced daytime wheeze and improved morning peak
expiratory flow, but did not improve night awakenings,
use of b-agonists, or FEV1 (36). It was suggested that the
FEV1 was quite high in these subjects, and difficult to
improve (36).
Glucocorticoids improve FEV1 in subjects with asthma.
Thus, it seems unlikely that Lyprinol will replace the
steroids in the treatment of mild asthma. A clinical trial
determining the effect of Lyprinol on the FEV1 in sub-
jects with more severe asthma would be on interest. One
point in favour of the use of Lyprinol is that the small
benefits come with no excess of adverse effects (36).
In their labelling, Blackmores have emphasized that
there is good clinical evidence that Lyprinol causes a
small improvement in lung function, rather than any ben-
eficial effects in arthritis. This labelling is supported by
the clinical trials with Lyprinol reported here.
Studies Comparing the Anti-inflammatory
Effects of Lyprinol and Fish Oil
EPA and DHA are the main constituents of fish oil sup-
plements. Fish oil is probably anti-inflammatory because,
like Lyprinol, it inhibits the production of eicosanoids
and cytokines (37). Recently, a direct comparison of
Lyprinol and fish oil preparations (Blackmore’s), avail-
able in Australia, has shown EPA (1 mgml–1) inhibits
COX-1 and COX-2 by 92% and 91%, and DHA inhibits
by 65% and 95%, respectively (13). These values are
mainly higher than the inhibition observed with
Lyprinol and its free fatty acid extracts (values given
previously), probably because the levels of EPA and
DHA in Lyprinol are lower than in preparations of
EPA or DHA (13). However, when Lyprinol is hydro-
lysed it has a similar ability to inhibit the COX enzymes
as fish oil (13).
The evidence that fish oil is anti-inflammatory when
used clinically as an adjunct in rheumatoid arthritis is
quite good (38). However, the evidence for clinical effi-
cacy for fish oil in osteoarthritis and asthma is weak (37).
There is a clinical trial showing that the combination
of Lyprinol, EPA, and DHA are effective and well-
tolerated in the treatment of rheumatoid arthritis (34).
Unfortunately, the effects of the combination were not
compared to Lyprinol alone, or EPA/DHA alone, in
this study, making it impossible to determine whether
any of the benefit was due to Lyprinol, or whether
Lyprinol has added benefits to EPA/DHA. Thus, head
to head trials of Lyprinol and fish oil should be
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undertaken in subjects with rheumatoid arthritis, prefer-
able with a placebo group.
In a mouse model of inflammatory bowel disease,
Lyprinol 5mg/day prevented body weight loss whereas
EPA/DHA 55mg/day did not (22). Lyprinol was also
more effective than the EPA/DHA in reducing disease
activity index, which included body weight loss, rectal
bleeding, stool consistency, and overall condition
(22). Lyprinol increased the crypt area index, whereas
EPA/DHA did not (22). To date, the clinical trials of
Lyprinol in inflammatory bowel disease have not been
reported. Clinical trials of fish oil in Crohn’s disease
(39) and ulcerative colitis (40) have not shown clear cut
benefits. A clinical trial of Lyprinol alone in inflamma-
tory bowel disease is indicated.
In summary, there is weak evidence that fish oil
and Lyprinol have a small benefit in osteoarthritis,
rheumatoid arthritis, and asthma, and as clinical anti-
inflammatory agents there is little to choose between
them. Fish oil does have the benefit of being antithrom-
botic, and reducing the incidence of coronary heart dis-
ease and stroke. Thus, in subjects with arthritis at high
cardiovascular risk, fish oil may have a better overall
effect than Lyprinol.
Conclusion
The experimental evidence that Lyprinol has anti-inflam-
matory effects is good, and consequently it may work in
humans. There is lot of hype about the clinical uses of
Lyprinol on the Web (and in the wider media over the
years), but much of it is not supported by good clinical
trials. Appropriate clinical trials have not been underta-
ken. For instance, both randomized, double-blind,
placebo-controlled trials and comparator trials with stan-
dard drugs need to be undertaken, with Lyprinol in rheu-
matoid arthritis and osteoarthritis. Without good clinical
trials, we cannot conclude that Lyprinol is effective or
ineffective in human inflammation. No adverse effects
have been reported with Lyprinol. Thus, although it is
difficult to conclude from the completed clinical trials
whether it does much good, it can be concluded that
Lyprinol probably does no harm.
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